Aktive Positionen von Howard Davis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Direktor/Vorstandsmitglied | 11.08.2022 | - |
| Vorstandsvorsitzender | 11.08.2022 | - |
Karriereverlauf von Howard Davis
Ehemalige bekannte Positionen von Howard Davis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| THIRD HARMONIC BIO, INC. | Geschäftsführer | - | - |
Statistik
International
| Vereinigte Staaten | 2 |
| Vereinigtes Königreich | 2 |
Operativ
| Chief Operating Officer | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| THIRD HARMONIC BIO, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Howard Davis
- Erfahrung
